B. Riley Predicts Reduced Earnings for ClearPoint Neuro

ClearPoint Neuro, Inc. (NASDAQ:CLPT) – B. Riley reduced their FY2025 earnings per share estimates for ClearPoint Neuro in a research note issued on Sunday, November 9th. B. Riley analyst A. Schock now expects that the company will post earnings per share of ($0.85) for the year, down from their prior forecast of ($0.81). The consensus estimate for ClearPoint Neuro’s current full-year earnings is ($0.66) per share. B. Riley also issued estimates for ClearPoint Neuro’s Q4 2025 earnings at ($0.22) EPS, Q1 2026 earnings at ($0.22) EPS, Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.17) EPS, Q4 2026 earnings at ($0.16) EPS and FY2026 earnings at ($0.75) EPS.

ClearPoint Neuro (NASDAQ:CLPT) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.01). ClearPoint Neuro had a negative return on equity of 94.44% and a negative net margin of 66.15%.The company had revenue of $5.36 million during the quarter, compared to the consensus estimate of $9.60 million. ClearPoint Neuro has set its FY 2025 guidance at EPS.

Several other brokerages have also commented on CLPT. Weiss Ratings restated a “sell (d-)” rating on shares of ClearPoint Neuro in a report on Wednesday, October 8th. Wall Street Zen upgraded ClearPoint Neuro from a “sell” rating to a “hold” rating in a research note on Saturday, September 13th. Finally, Stifel Nicolaus increased their price objective on ClearPoint Neuro from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Friday, August 1st. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $19.67.

ClearPoint Neuro Price Performance

Shares of NASDAQ CLPT opened at $17.40 on Wednesday. ClearPoint Neuro has a 1 year low of $9.76 and a 1 year high of $30.10. The company has a debt-to-equity ratio of 1.46, a current ratio of 7.30 and a quick ratio of 6.45. The company’s 50-day moving average is $19.58 and its 200 day moving average is $14.58. The stock has a market capitalization of $494.63 million, a P/E ratio of -21.48 and a beta of 1.28.

Insider Transactions at ClearPoint Neuro

In other ClearPoint Neuro news, CEO Joseph Burnett sold 26,463 shares of ClearPoint Neuro stock in a transaction on Friday, October 10th. The stock was sold at an average price of $26.98, for a total transaction of $713,971.74. Following the completion of the transaction, the chief executive officer owned 217,059 shares in the company, valued at approximately $5,856,251.82. The trade was a 10.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 6.97% of the company’s stock.

Hedge Funds Weigh In On ClearPoint Neuro

Several institutional investors and hedge funds have recently modified their holdings of CLPT. Goldman Sachs Group Inc. increased its stake in ClearPoint Neuro by 98.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 257,871 shares of the company’s stock valued at $3,066,000 after purchasing an additional 127,823 shares in the last quarter. Lane Generational LLC grew its holdings in shares of ClearPoint Neuro by 53.5% during the first quarter. Lane Generational LLC now owns 242,045 shares of the company’s stock valued at $2,878,000 after buying an additional 84,350 shares during the last quarter. Deutsche Bank AG bought a new stake in shares of ClearPoint Neuro during the first quarter valued at approximately $63,000. AlphaQuest LLC increased its position in shares of ClearPoint Neuro by 433.5% during the second quarter. AlphaQuest LLC now owns 9,411 shares of the company’s stock valued at $112,000 after acquiring an additional 7,647 shares in the last quarter. Finally, MGO One Seven LLC raised its holdings in ClearPoint Neuro by 9.6% in the 2nd quarter. MGO One Seven LLC now owns 17,949 shares of the company’s stock worth $214,000 after acquiring an additional 1,569 shares during the last quarter. 30.08% of the stock is currently owned by institutional investors.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.